Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow SeriesNewsfile Corp · 5 days ago
Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug SubstanceNewsfile Corp · Oct 13, 2026
Phio Pharmaceuticals Highlights 85% Response Rate as PH-762 Nears Phase 2bDefense World · Oct 11, 2026
Phio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026Newsfile Corp · Oct 6, 2026
Phio Pharmaceuticals to Present at the National Investment Banking Association (NIBA) 153rd ConferenceNewsfile Corp · Oct 5, 2026
Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 ConferenceNewsfile Corp · Sep 23, 2026Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.36 | -$0.36 | Beat |
| May 7, 2026 | -$0.24 | -$0.34 | Miss |
| Mar 5, 2026 | -$0.34 | -$0.15 | Beat |
| Nov 13, 2025 | -$0.45 | -$0.44 | Beat |
| Aug 14, 2025 | -$0.36 | -$0.45 | Miss |
| May 15, 2025 | – | -$0.41 |